Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Eisai In $205 Million Acquisition of Four Oncology-Related Products


WASHINGTON, D.C., September 13, 2006   Covington represented both Eisai Co., Ltd. and Eisai Inc. in the recent $205 million product acquisition agreement with Ligand Pharmaceuticals.  Eisai obtained exclusive global rights to four products, including ONTAK®, Targretin® capsules, Targretin® 1% gel and Panretin® 0.1% gel. 

This acquisition will help to establish Eisai’s global oncology business, which is one of the company’s long-standing therapeutic areas of focus.  Eisai Co., Ltd., based in Tokyo, is a research-based human health care company that develops and markets products across the world.  Eisai Inc. is a United States pharmaceutical subsidiary.  The transaction is expected to close before the end of the year, subject to government approval.

Covington’s corporate team included Catherine Dargan, John Hurvitz, Marianna Horton, Michael Riella, and Heather Davis.  Peter Safir, Stefanie Doebler, Natalie Derzko, Scott Schrader, Tom Bradshaw, Kathleen Gallagher-Duff, James Dean, Gunnar Wolf, Scott Feldstein, Robert Heller, Eli Hoory, Julie Edmond and Mary DeYoung also advised on the regulatory, intellectual property, and tax aspects of the transaction.

Share this article: